Catalyst Pharmaceutical Partners shares owned by Federated Investors
Quarter-by-quarter ownership of Catalyst Pharmaceutical Partners (CPRX) shares owned by Federated Investors
from 13F filings
Historical chart of Federated Investors investment in Catalyst Pharmaceutical Partners
Tip: Access up to 7 years of quarterly data
All positions including Catalyst Pharmaceutical Partners held by Federated Investors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Catalyst Pharmaceutical Partners by Federated Investors
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2024-09-30 | $1.1M | 54k | 19.88 |
| 2024-06-30 | $836k | 54k | 15.49 |
| 2024-03-31 | $861k | 54k | 15.94 |
| 2023-12-31 | $2.2M | 129k | 16.81 |
| 2023-09-30 | $2.0M | 171k | 11.69 |
| 2023-06-30 | $1.3M | 95k | 13.44 |
| 2023-03-31 | $684k | 41k | 16.58 |
| 2022-12-31 | $771k | 41k | 18.67 |
| 2022-09-30 | $53k | 210 | 250.00 |
| 2022-06-30 | $351k | 1.1k | 333.33 |
| 2022-03-31 | $164M | 656k | 250.00 |
| 2021-12-31 | $658M | 658k | 1000.00 |
| 2021-09-30 | $3.5M | 657k | 5.30 |
| 2021-06-30 | $3.6M | 627k | 5.75 |
| 2021-03-31 | $2.9M | 627k | 4.61 |
| 2020-12-31 | $2.2M | 632k | 3.43 |
| 2020-09-30 | $1.8M | 633k | 2.90 |
| 2020-06-30 | $2.6M | 559k | 4.64 |
| 2020-03-31 | $992k | 261k | 3.80 |
| 2019-12-31 | $36k | 9.3k | 3.83 |
| 2019-09-30 | $686k | 123k | 5.59 |
| 2019-06-30 | $6.7k | 1.9k | 3.46 |
| 2017-12-31 | $2.0k | 597 | 3.35 |
| 2016-03-31 | $6.0M | 5.1M | 1.17 |
| 2015-12-31 | $11M | 4.6M | 2.45 |
| 2015-09-30 | $14M | 4.6M | 3.00 |
| 2015-06-30 | $19M | 4.6M | 4.13 |
| 2015-03-31 | $8.6M | 2.0M | 4.33 |
| 2014-12-31 | $4.3M | 1.4M | 2.97 |
| 2014-09-30 | $10M | 3.0M | 3.32 |
| 2014-06-30 | $8.1M | 3.2M | 2.53 |
| 2014-03-31 | $7.4M | 3.3M | 2.26 |
| 2013-12-31 | $6.3M | 3.3M | 1.95 |
| 2013-09-30 | $10M | 3.3M | 3.05 |
| 2013-06-30 | $3.6M | 4.0M | 0.89 |
Top funds holding Catalyst Pharmaceutical Partners
View all funds holding Catalyst Pharmaceutical Partners